CN112210537A - 肝癌类器官及其培养方法、培养用培养基和用途 - Google Patents
肝癌类器官及其培养方法、培养用培养基和用途 Download PDFInfo
- Publication number
- CN112210537A CN112210537A CN202011042946.6A CN202011042946A CN112210537A CN 112210537 A CN112210537 A CN 112210537A CN 202011042946 A CN202011042946 A CN 202011042946A CN 112210537 A CN112210537 A CN 112210537A
- Authority
- CN
- China
- Prior art keywords
- liver cancer
- concentration
- culture
- culture medium
- vol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 129
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 126
- 239000001963 growth medium Substances 0.000 title claims abstract description 67
- 210000002220 organoid Anatomy 0.000 title claims abstract description 55
- 238000012136 culture method Methods 0.000 title abstract description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 64
- 210000001519 tissue Anatomy 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 37
- 102000004877 Insulin Human genes 0.000 claims abstract description 32
- 108090001061 Insulin Proteins 0.000 claims abstract description 32
- 229940125396 insulin Drugs 0.000 claims abstract description 32
- 238000012258 culturing Methods 0.000 claims abstract description 28
- 239000000126 substance Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 108010082117 matrigel Proteins 0.000 claims abstract description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 42
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 26
- 229960005322 streptomycin Drugs 0.000 claims description 21
- 239000002609 medium Substances 0.000 claims description 14
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 13
- 239000012583 B-27 Supplement Substances 0.000 claims description 13
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 13
- 239000012580 N-2 Supplement Substances 0.000 claims description 13
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 12
- 229960004308 acetylcysteine Drugs 0.000 claims description 12
- 229940045997 vitamin a Drugs 0.000 claims description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 11
- 239000012574 advanced DMEM Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 10
- 102000057243 human FGF10 Human genes 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 102000029816 Collagenase Human genes 0.000 claims description 8
- 108060005980 Collagenase Proteins 0.000 claims description 8
- 229960002424 collagenase Drugs 0.000 claims description 8
- 238000007877 drug screening Methods 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 238000010171 animal model Methods 0.000 claims description 5
- 239000000413 hydrolysate Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 6
- 239000007995 HEPES buffer Substances 0.000 claims 6
- 238000000338 in vitro Methods 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 49
- 210000000056 organ Anatomy 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- -1 HEPES Substances 0.000 description 4
- 210000003701 histiocyte Anatomy 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- KCVLOUPMDNWZLV-UHFFFAOYSA-N [Na+].[O-]C1OC=CC=C1 Chemical compound [Na+].[O-]C1OC=CC=C1 KCVLOUPMDNWZLV-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012592 cell culture supplement Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
组别 | 培养成功例数/总例数 | 培养成功率(%) |
实施例1 | 18/21 | 85.71 |
实施例3 | 17/21 | 80.95 |
实施例4 | 16/21 | 76.19 |
实施例5 | 12/21 | 57.14 |
实施例6 | 14/21 | 66.66 |
对比例1 | 3/21 | 14.29 |
对比例2 | 5/21 | 23.81 |
对比例3 | 7/21 | 33.33 |
组别 | Z因子 | 信号噪音比(S/N) | 信号背景比(S/B) |
实施例1 | 1.10 | 24.37 | 10.19 |
实施例3 | 0.88 | 18.31 | 8.56 |
实施例4 | 0.96 | 20.17 | 9.10 |
实施例5 | 0.82 | 17.69 | 8.01 |
实施例6 | 0.76 | 17.83 | 5.62 |
对比例1 | 0.12 | 2.36 | 1.93 |
对比例2 | 0.19 | 3.18 | 2.00 |
对比例3 | 0.23 | 4.25 | 2.65 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011042946.6A CN112210537B (zh) | 2020-09-28 | 2020-09-28 | 肝癌类器官及其培养方法、培养用培养基和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011042946.6A CN112210537B (zh) | 2020-09-28 | 2020-09-28 | 肝癌类器官及其培养方法、培养用培养基和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112210537A true CN112210537A (zh) | 2021-01-12 |
CN112210537B CN112210537B (zh) | 2022-03-11 |
Family
ID=74052338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011042946.6A Active CN112210537B (zh) | 2020-09-28 | 2020-09-28 | 肝癌类器官及其培养方法、培养用培养基和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112210537B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112680398A (zh) * | 2021-01-18 | 2021-04-20 | 南昌五元生物科技有限公司 | 用于可室温保存类器官的培养基及维持类器官生长活性的方法 |
CN113481162A (zh) * | 2021-07-01 | 2021-10-08 | 丹望医疗科技(上海)有限公司 | 用于快速培养肿瘤类器官的培养基、方法以及试剂盒 |
CN115521912A (zh) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | 一种以类器官与t细胞共培养的免疫细胞治疗方法及应用 |
CN115521898A (zh) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | 肝癌类器官与nk细胞共培养的免疫细胞治疗方法及应用 |
CN115537395A (zh) * | 2021-11-04 | 2022-12-30 | 上海万何圆生物科技有限公司 | 一种肝癌类器官与TILs细胞共培养的治疗方法及其应用 |
WO2023035299A1 (zh) * | 2021-09-08 | 2023-03-16 | 合肥中科普瑞昇生物医药科技有限公司 | 一种用于肝癌类器官培养的培养基、及其培养方法和应用 |
WO2023060695A1 (zh) * | 2021-10-14 | 2023-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | 肝癌悬浮类器官的培养基和培养方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110878286A (zh) * | 2019-12-24 | 2020-03-13 | 江苏信安佳医疗科技有限公司 | 一种用于肝癌类器官细胞球培养的培养基 |
-
2020
- 2020-09-28 CN CN202011042946.6A patent/CN112210537B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110878286A (zh) * | 2019-12-24 | 2020-03-13 | 江苏信安佳医疗科技有限公司 | 一种用于肝癌类器官细胞球培养的培养基 |
Non-Patent Citations (1)
Title |
---|
蔡觅等: "胰岛素样生长因子系统与肝癌", 《中国生物化学与分子生物学报》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112680398A (zh) * | 2021-01-18 | 2021-04-20 | 南昌五元生物科技有限公司 | 用于可室温保存类器官的培养基及维持类器官生长活性的方法 |
CN112680398B (zh) * | 2021-01-18 | 2023-03-17 | 南昌五元生物科技有限公司 | 用于可室温保存类器官的培养基及维持类器官生长活性的方法 |
CN113481162A (zh) * | 2021-07-01 | 2021-10-08 | 丹望医疗科技(上海)有限公司 | 用于快速培养肿瘤类器官的培养基、方法以及试剂盒 |
CN113481162B (zh) * | 2021-07-01 | 2023-02-24 | 丹望医疗科技(上海)有限公司 | 用于快速培养肿瘤类器官的培养基、方法以及试剂盒 |
WO2023035299A1 (zh) * | 2021-09-08 | 2023-03-16 | 合肥中科普瑞昇生物医药科技有限公司 | 一种用于肝癌类器官培养的培养基、及其培养方法和应用 |
WO2023060695A1 (zh) * | 2021-10-14 | 2023-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | 肝癌悬浮类器官的培养基和培养方法 |
CN115521912A (zh) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | 一种以类器官与t细胞共培养的免疫细胞治疗方法及应用 |
CN115521898A (zh) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | 肝癌类器官与nk细胞共培养的免疫细胞治疗方法及应用 |
CN115537395A (zh) * | 2021-11-04 | 2022-12-30 | 上海万何圆生物科技有限公司 | 一种肝癌类器官与TILs细胞共培养的治疗方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112210537B (zh) | 2022-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112210537B (zh) | 肝癌类器官及其培养方法、培养用培养基和用途 | |
WO2021088119A1 (zh) | 原代乳腺上皮细胞培养基、培养方法及其应用 | |
CN111575237B (zh) | 一种乳腺癌无支架类器官专用培养基及培养方法 | |
Mirzaeian et al. | Optimizing the cell seeding protocol to human decellularized ovarian scaffold: application of dynamic system for bio-engineering | |
CN108504625B (zh) | 一种小鼠成纤维细胞及其用途 | |
CN111040997A (zh) | 一种具有肿瘤免疫微环境的前列腺癌类器官培养及冻存方法 | |
CN112080471A (zh) | 顺铂耐药肺癌类器官及其培养方法、培养用培养基和用途 | |
CN109430252A (zh) | 一种干细胞冻存液及其制作方法 | |
CN111040996B (zh) | 一种制备卵巢癌类器官的方法 | |
CN114426949B (zh) | 一种建立胰腺或胰腺癌类器官的培养基及方法和应用 | |
Carter et al. | A three-dimensional organoid model of primary breast cancer to investigate the effects of oncolytic virotherapy | |
Tang-Schomer et al. | 3D patient-derived tumor models to recapitulate pediatric brain tumors In Vitro | |
Gao et al. | Comparison of yield, purity, and functional properties of large-volume exosome isolation using ultrafiltration and polymer-based precipitation | |
Ma et al. | Do patient-derived spheroid culture models have relevance in chondrosarcoma research? | |
Rubin et al. | Encapsulation of adipogenic factors to promote differentiation of adipose-derived stem cells | |
WO2023217130A1 (zh) | 包含骨骼肌前体样细胞的生物制剂及其制备方法和应用 | |
CN112210538A (zh) | 一种人食管鳞癌细胞系ncce1、建立方法及其应用 | |
CN109652377B (zh) | 一种肺癌干细胞的制备方法及应用 | |
CN111424015A (zh) | 用于前列腺肿瘤细胞的培养基和三维培养方法 | |
CN111849904B (zh) | 神经母细胞瘤类器官的培养基、培养方法及移植体 | |
CN114317442A (zh) | 一种建立乳腺类器官或/和乳腺癌类器官的培养基及方法和应用 | |
CN112760289A (zh) | 一种乳腺癌类器官专用培养基及3d培养方法 | |
WO2016146893A1 (en) | Human tumor based extracellular matrix for cell studies in vitro | |
WO2024065883A1 (zh) | 一种用于鼻咽癌类器官培养的培养基、及其培养方法和应用 | |
Gómez-Álvarez et al. | Addressing Key Questions in Organoid Models: Who, Where, How, and Why? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210219 Address after: 100176 Room 302, unit 2, building 7, huilongsen Science Park, Daxing Economic and Technological Development Zone, Beijing Applicant after: Beijing Ke Ke medical science and Technology Co.,Ltd. Applicant after: ZHEJIANG K2ONCOLOGY Co.,Ltd. Address before: Room 1001, 10th floor, building 6, No. 1366, Hongfeng Road, Huzhou City, Zhejiang Province, 313000 Applicant before: ZHEJIANG K2ONCOLOGY Co.,Ltd. Applicant before: Beijing Ke Ke medical science and Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 101111, 5th Floor, Building 3, Zone 3, No. 88 Jinghai Fifth Road, Daxing District Economic and Technological Development Zone, Beijing Patentee after: Beijing Ke Ke medical science and Technology Co.,Ltd. Country or region after: China Patentee after: ZHEJIANG K2ONCOLOGY Co.,Ltd. Address before: 100176 Room 302, unit 2, building 7, huilongsen Science Park, Daxing Economic and Technological Development Zone, Beijing Patentee before: Beijing Ke Ke medical science and Technology Co.,Ltd. Country or region before: China Patentee before: ZHEJIANG K2ONCOLOGY Co.,Ltd. |